Molecular Templates Management
Management criteria checks 3/4
Molecular Templates' CEO is Eric Poma, appointed in Jan 2009, has a tenure of 15.33 years. total yearly compensation is $857.77K, comprised of 72.4% salary and 27.6% bonuses, including company stock and options. directly owns 0.28% of the company’s shares, worth $25.91K. The average tenure of the management team and the board of directors is 0.8 years and 6.8 years respectively.
Key information
Eric Poma
Chief executive officer
US$857.8k
Total compensation
| CEO salary percentage | 72.4% |
| CEO tenure | 15.3yrs |
| CEO ownership | 0.3% |
| Management average tenure | less than a year |
| Board average tenure | 6.8yrs |
Recent management updates
Recent updates
Little Excitement Around Molecular Templates, Inc.'s (NASDAQ:MTEM) Revenues As Shares Take 48% Pounding
Apr 03
Lacklustre Performance Is Driving Molecular Templates, Inc.'s (NASDAQ:MTEM) 26% Price Drop
Dec 20There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 45% Share Price Rise
Apr 17What Does The Future Hold For Molecular Templates, Inc. (NASDAQ:MTEM)? These Analysts Have Been Cutting Their Estimates
Nov 16Time To Worry? Analysts Are Downgrading Their Molecular Templates, Inc. (NASDAQ:MTEM) Outlook
Aug 14Molecular Templates GAAP EPS of -$0.44 misses by $0.01, revenue of $4.42M misses by $2.6M
Aug 11Rock star Growth Puts Molecular Templates (NASDAQ:MTEM) In A Position To Use Debt
Apr 29Health Check: How Prudently Does Molecular Templates (NASDAQ:MTEM) Use Debt?
Dec 30Some Analysts Just Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates
Nov 25Is Molecular Templates (NASDAQ:MTEM) Using Debt In A Risky Way?
Sep 22News Flash: Analysts Just Made A Notable Upgrade To Their Molecular Templates, Inc. (NASDAQ:MTEM) Forecasts
Aug 15Need To Know: Analysts Just Made A Substantial Cut To Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates
May 18Brokers Are Upgrading Their Views On Molecular Templates, Inc. (NASDAQ:MTEM) With These New Forecasts
Mar 21Need To Know: The Consensus Just Cut Its Molecular Templates, Inc. (NASDAQ:MTEM) Estimates For 2021
Feb 21Is Molecular Templates (NASDAQ:MTEM) A Risky Investment?
Jan 26
Molecular Templates updates on study of MT5111, plans breast cancer expansion cohort in 1H21
Dec 22Here's What We Think About Molecular Templates' (NASDAQ:MTEM) CEO Pay
Dec 04Molecular Templates: Progress Stalled As Partial Hold Placed On Pivotal ETB Trial
Nov 17CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$858k | US$621k | -US$8m |
| Sep 30 2023 | n/a | n/a | -US$26m |
| Jun 30 2023 | n/a | n/a | -US$47m |
| Mar 31 2023 | n/a | n/a | -US$60m |
| Dec 31 2022 | US$2m | US$600k | -US$93m |
| Sep 30 2022 | n/a | n/a | -US$81m |
| Jun 30 2022 | n/a | n/a | -US$87m |
| Mar 31 2022 | n/a | n/a | -US$78m |
| Dec 31 2021 | US$4m | US$577k | -US$83m |
| Sep 30 2021 | n/a | n/a | -US$101m |
| Jun 30 2021 | n/a | n/a | -US$94m |
| Mar 31 2021 | n/a | n/a | -US$110m |
| Dec 31 2020 | US$5m | US$560k | -US$105m |
| Sep 30 2020 | n/a | n/a | -US$92m |
| Jun 30 2020 | n/a | n/a | -US$107m |
| Mar 31 2020 | n/a | n/a | -US$85m |
| Dec 31 2019 | US$2m | US$515k | -US$69m |
| Sep 30 2019 | n/a | n/a | -US$60m |
| Jun 30 2019 | n/a | n/a | -US$27m |
| Mar 31 2019 | n/a | n/a | -US$28m |
| Dec 31 2018 | US$4m | US$500k | -US$30m |
| Sep 30 2018 | n/a | n/a | -US$31m |
| Jun 30 2018 | n/a | n/a | -US$36m |
| Mar 31 2018 | n/a | n/a | -US$31m |
| Dec 31 2017 | US$3m | US$448k | -US$24m |
Compensation vs Market: Eric's total compensation ($USD857.77K) is about average for companies of similar size in the US market ($USD664.85K).
Compensation vs Earnings: Eric's compensation has been consistent with company performance over the past year.
CEO
Eric Poma (51 yo)
15.3yrs
Tenure
US$857,769
Compensation
Dr. Eric E. Poma, Ph D., is the Chief Executive Officer and Chief Scientific Officer of Molecular Templates, Inc. since 2009 and served as its President. Dr. Poma founded Private Molecular in February 2009...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Chief Scientific Officer & Director | 15.3yrs | US$857.77k | 0.28% $ 25.9k | |
| President | 1.3yrs | US$579.24k | 0.097% $ 8.9k | |
| Chief Operating Officer | less than a year | no data | no data | |
| Chief Strategy Officer & Head of IR | less than a year | no data | no data | |
| Senior VP & Head of CMC Development | no data | no data | no data | |
| Senior VP and Head of Preclinical Development & Translational Medicine | less than a year | no data | no data |
0.8yrs
Average Tenure
51yo
Average Age
Experienced Management: MTEM's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Chief Scientific Officer & Director | 6.8yrs | US$857.77k | 0.28% $ 25.9k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 6.8yrs | US$59.29k | 0% $ 0 | |
| Independent Chairman | 6.8yrs | US$87.29k | 0.041% $ 3.8k | |
| Independent Director | 6.8yrs | US$54.29k | 0% $ 0 | |
| Independent Director | 4.4yrs | US$49.29k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Director | 2.2yrs | US$561.35k | 0% $ 0 |
6.8yrs
Average Tenure
66yo
Average Age
Experienced Board: MTEM's board of directors are considered experienced (6.8 years average tenure).